{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:26:46Z","timestamp":1793896006670,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2025ZDZX0046"],"award-info":[{"award-number":["2025ZDZX0046"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110179","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T14:17:47Z","timestamp":1782656267000},"page":"110179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Noninvasive deciphering of the immunosuppressive tumor microenvironment and evaluation of MerTK inhibitor mediated reversal of ICB resistance via MerTK-targeted PET"],"prefix":"10.1016","volume":"180","author":[{"given":"Yunyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.110179_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110179_bb0010","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/1078-0432.CCR-16-3079","article-title":"Challenges and opportunities in adapting clinical trial design for immunotherapies","volume":"23","author":"Siu","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110179_bb0015","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110179_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/OP.22.00762","article-title":"Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer: shedding light on the future","volume":"19","author":"Sahin","year":"2023","journal-title":"JCO Oncol. Pract."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110179_bb0025","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1172\/JCI120775","article-title":"Emerging strategies for combination checkpoint modulators in cancer immunotherapy","volume":"128","author":"Popovic","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110179_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105158","article-title":"Multi-omics perspective reveals the different patterns of tumor immune microenvironment based on programmed death ligand 1 (PD-L1) expression and predictor of responses to immune checkpoint blockade across pan-cancer","volume":"22","author":"Huang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110179_bb0035","doi-asserted-by":"crossref","first-page":"11733","DOI":"10.1007\/s00210-025-04131-w","article-title":"Emerging new immune checkpoint inhibitors in solid tumor immunotherapy","volume":"398","author":"Poorkhani","year":"2025","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"Pt 3","key":"10.1016\/j.bioorg.2026.110179_bb0040","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.semcancer.2022.02.019","article-title":"Resistance to immune checkpoint blockade: mechanisms, counter-acting approaches, and future directions","volume":"86","author":"Haddad","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"23","key":"10.1016\/j.bioorg.2026.110179_bb0045","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110179_bb0050","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/978-3-030-79308-1_19","article-title":"Cancer imaging in immunotherapy","volume":"1342","author":"Ak","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110179_bb0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s41669-025-00557-3","article-title":"Very early health technology assessment for potential predictive biomarkers in the treatment of advanced non-small cell lung cancer","volume":"9","author":"Otten","year":"2025","journal-title":"Pharmacoecon Open"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110179_bb0060","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/jpm12071073","article-title":"Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems","volume":"12","author":"Marletta","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.bioorg.2026.110179_bb0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110179_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102431","article-title":"Concordance, correlation, and clinical impact of standardized PD-L1 and TIL scoring in SCCHN","volume":"14","author":"De Keukeleire","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110179_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2019.08.009","article-title":"Noninvasive imaging in cancer immunotherapy: the way to precision medicine","volume":"466","author":"Du","year":"2019","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110179_bb0080","doi-asserted-by":"crossref","first-page":"13362","DOI":"10.1038\/s41598-019-50079-2","article-title":"(18)F-FDG uptake in PET\/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer","volume":"9","author":"Takada","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110179_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2013.06.012","article-title":"Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients","volume":"25","author":"Tagliabue","year":"2014","journal-title":"Eur. J. Intern. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110179_bb0090","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.cco.0000128276.13585.fa","article-title":"Positron emission tomography in gastric and esophageal cancer","volume":"16","author":"Flamen","year":"2004","journal-title":"Curr. Opin. Oncol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110179_bb0095","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/0008-5472.CAN-16-3346","article-title":"Granzyme B PET imaging as a predictive biomarker of immunotherapy response","volume":"77","author":"Larimer","year":"2017","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110179_bb0100","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","article-title":"The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by Granzyme B PET imaging","volume":"25","author":"Larimer","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110179_bb0105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162962","article-title":"Functional imaging of immune cell subpopulations in the tumor microenvironment: clinical implications","volume":"132","author":"Heimberger","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110179_bb0110","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2967\/jnumed.123.266888","article-title":"Noninvasively deciphering the immunosuppressive tumor microenvironment using galectin-1 PET to inform immunotherapy responses","volume":"65","author":"Liu","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110179_bb0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/cbmi.4c00030","article-title":"Peptide PET imaging: a review of recent developments and a look at the future of Radiometal-labeled peptides in medicine","volume":"2","author":"Shabsigh","year":"2024","journal-title":"Chem. Biomed. Imaging"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110179_bb0120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/cbmi.4c00117","article-title":"Positron emission tomography imaging of the adaptive immune system in cardiovascular diseases","volume":"3","author":"Otaegui","year":"2025","journal-title":"Chem. Biomed. Imaging"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110179_bb0125","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1021\/cbmi.5c00133","article-title":"Folate receptor alpha targeted immuno-positron emission tomography probe for noninvasive imaging in triple-negative breast cancer","volume":"4","author":"Ma","year":"2026","journal-title":"Chem. Biomed. Imaging"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110179_bb0130","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110179_bb0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","article-title":"TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer","volume":"100","author":"Linger","year":"2008","journal-title":"Adv. Cancer Res."},{"issue":"22","key":"10.1016\/j.bioorg.2026.110179_bb0140","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.3390\/cancers13225639","article-title":"Targeting MERTK and AXL in EGFR mutant non-small cell lung Cancer","volume":"13","author":"Yan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110179_bb0145","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pcmr.12110","article-title":"MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL","volume":"26","author":"Tworkoski","year":"2013","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"57","key":"10.1016\/j.bioorg.2026.110179_bb0150","doi-asserted-by":"crossref","first-page":"96656","DOI":"10.18632\/oncotarget.3750","article-title":"MerTK is a novel therapeutic target in gastric cancer","volume":"8","author":"Yi","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110179_bb0155","article-title":"Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110179_bb0160","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41467-019-09233-7","article-title":"MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression","volume":"10","author":"Jiang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110179_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107577","article-title":"MERTK in cancer therapy: targeting the receptor tyrosine kinase in tumor cells and the immune system","volume":"213","author":"Huelse","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110179_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124184","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models","volume":"3","author":"Du","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bioorg.2026.110179_bb0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-immunol-032414-112103","article-title":"TAM receptor signaling in immune homeostasis","volume":"33","author":"Rothlin","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110179_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113822","article-title":"Development of [(18)F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease","volume":"226","author":"Wong","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110179_bb0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0959-8049(14)70629-X","article-title":"503 UNC2025: a small molecule inhibitor of merTK with efficacy in mouse melanoma models","volume":"50","author":"Earp","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110179_bb0190","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1021\/jm500749d","article-title":"UNC2025, a potent and orally bioavailable MER\/FLT3 dual inhibitor","volume":"57","author":"Zhang","year":"2014","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110179_bb0195","doi-asserted-by":"crossref","first-page":"19813","DOI":"10.1021\/acs.jmedchem.4c02156","article-title":"Preliminary study of radionuclide-labeled MerTK-targeting PET imaging agents for the diagnosis of melanoma","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110179_bb0200","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/molecules27051460","article-title":"The synthesis and initial evaluation of MerTK targeted PET agents","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110179_bb0205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","article-title":"Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer","volume":"11","author":"Drake","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110179_bb0210","article-title":"Unraveling the immune evasion mechanisms in the tumor microenvironment of head and neck squamous cell carcinoma","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110179_bb0215","first-page":"21","article-title":"Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for cold-to-hot tumor transformation","volume":"8","author":"Yu","year":"2025","journal-title":"Cancer Drug Resist."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:56:47Z","timestamp":1793894207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S0045206826007157"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110179","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive deciphering of the immunosuppressive tumor microenvironment and evaluation of MerTK inhibitor mediated reversal of ICB resistance via MerTK-targeted PET","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110179"}}